Man & Science Closes €7.4 Million in Capital Increase

Man & Science announces U.S. FDA Breakthrough Device Designation Granted for the treatment of Chronic Cluster Headache

Man & Science announced today that it has been granted a Breakthrough Device Designation by the Center of Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) for its minimally invasive innovative neuromodulation therapy for the treatment of Chronic Cluster Headache (CCH).